AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
7,117.00
-146.60 (-2.02%)
As of 3:33PM GMT. Market open.
Stock chart is not supported by your current browser
Previous close7,263.60
Open7,190.00
Bid7,117.00 x 0
Ask7,120.00 x 0
Day's range7,114.00 - 7,322.00
52-week range5,626.00 - 8,227.88
Volume1,228,330
Avg. volume1,939,934
Market cap93.389B
Beta (5Y monthly)0.27
PE ratio (TTM)69.37
EPS (TTM)102.60
Earnings date29 Apr 2020
Forward dividend & yield2.18 (2.99%)
Ex-dividend date27 Feb 2020
1y target est78.83
  • Want to retire wealthy? I’d buy these 2 FTSE 100 dividend shares for a rising passive income
    Fool.co.uk

    Want to retire wealthy? I’d buy these 2 FTSE 100 dividend shares for a rising passive income

    These two FTSE 100 (INDEXFTSE:UKX) stocks have the pedigree to deliver long-term dividend income growth.The post Want to retire wealthy? I’d buy these 2 FTSE 100 dividend shares for a rising passive income appeared first on The Motley Fool UK.

  • The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, AstraZeneca and Duke Energy
    Zacks

    The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, AstraZeneca and Duke Energy

    The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, AstraZeneca and Duke Energy

  • Here’s why I’d invest £1,000 in these two FTSE 100 stocks in a Stocks and Shares ISA today
    Fool.co.uk

    Here’s why I’d invest £1,000 in these two FTSE 100 stocks in a Stocks and Shares ISA today

    These two FTSE 100 (INDEXFTSE:UKX) shares could offer impressive long-term returns in my opinion.The post Here's why I'd invest £1,000 in these two FTSE 100 stocks in a Stocks and Shares ISA today appeared first on The Motley Fool UK.

  • Why It Might Not Make Sense To Buy AstraZeneca PLC (LON:AZN) For Its Upcoming Dividend
    Simply Wall St.

    Why It Might Not Make Sense To Buy AstraZeneca PLC (LON:AZN) For Its Upcoming Dividend

    Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

  • Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
    Zacks

    Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

    AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

  • £2k spare? I’d aim to grow it with these FTSE 100 stocks right now!
    Fool.co.uk

    £2k spare? I’d aim to grow it with these FTSE 100 stocks right now!

    Could these two FTSE 100 shares help build your wealth and help you retire early?The post £2k spare? I’d aim to grow it with these FTSE 100 stocks right now! appeared first on The Motley Fool UK.

  • Here’s why Astrazeneca is one of the most expensive shares on the market
    Stockopedia

    Here’s why Astrazeneca is one of the most expensive shares on the market

    It has long been understood that cheap stocks have a tendency to outperform expensive stocks in the stock market. While this is not true every single year, ove8230;

  • Why I’d avoid AstraZeneca shares and buy this FTSE 100 stock
    Fool.co.uk

    Why I’d avoid AstraZeneca shares and buy this FTSE 100 stock

    Roland Head isn't comfortable with AstraZeneca's latest results. He reckons there's better value elsewhere in the FTSE 100 (INDEXFTSE: UKX).The post Why I'd avoid AstraZeneca shares and buy this FTSE 100 stock appeared first on The Motley Fool UK.

  • Reuters - UK Focus

    LIVE MARKETS-Closing snapshot: V-day of records

    * STOXX 600 hits fresh record highs * German GDP disappoints * EDF tops STOXX 600 after beating forecast * RBS shares drop after results Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London and Danilo Masoni (danilo.masoni@tr.com) in Milan. CLOSING SNAPSHOT: V-DAY OF RECORDS (1640 GMT) Here it comes a good reason to celebrate this Valentine's Day: the STOXX 600 hit record highs today, again!

  • AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
    Zacks

    AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

    AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

  • Reuters - UK Focus

    LIVE MARKETS-A rate cut every five days

    * STOXX 600 hits fresh record highs * German GDP disappoints * EDF tops STOXX 600 after beating forecast * RBS shares drop after results * Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London and Danilo Masoni (danilo.masoni@tr.com) in Milan. A RATE CUT EVERY FIVE DAYS (1405 GMT) When Mexico decided to cut rates yesterday little did they know they'd be the 800th to do so since the global financial crisis (H/T to BofA on the rate cut count).

  • Reuters - UK Focus

    GLOBAL MARKETS-European stocks climb to record on hopes of limited coronavirus economic hit

    Stock markets across the world ticked higher on Friday, as investors bet that the damage to the global economy from China's coronavirus outbreak would not be long-lasting. Europe's broad Euro STOXX 600 hit a record high, gaining 0.1% to mirror gains in Asia after a choppy start to the day. Indexes in London and Frankfurt gained 0.1% and 0.2% respectively, with the former moving higher after AstraZeneca shares turned positive.

  • Reuters - UK Focus

    LIVE MARKETS-Much love for France on Valentine's Day

    * STOXX 600 hits fresh record highs * German GDP disappoints * EDF tops STOXX 600 after beating forecast * RBS shares drop after results * Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters. You can share your thoughts with Thyagaraju Adinarayan (thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus (julien.ponthus@tr.com) in London and Danilo Masoni (danilo.masoni@tr.com) in Milan. MUCH LOVE FOR FRANCE ON VALENTINE'S DAY (1157 GMT) If you look at the top movers today, there is an eye-catching French utility topping the pan-European index: EDF - the stock gained more than 9% after the company beat forecasts.

  • AstraZeneca's CEO reaffirms 2021 targets
    Reuters

    AstraZeneca's CEO reaffirms 2021 targets

    AstraZeneca is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations. AstraZeneca is moving into a third year of sales growth after changes driven by Soriot and now has nine drugs with annual sales of more than $1 billion but analysts and investors have been looking for clues whether the company's earnings growth would keep up. The company's 2019 operating margin, or earnings before interest and tax over total revenue, was 26%.

  • Why I’d buy the AstraZeneca (AZN) share price for a second income stream
    Fool.co.uk

    Why I’d buy the AstraZeneca (AZN) share price for a second income stream

    The AstraZeneca (LON: AZN) share price is soaring, and here's why I think there's more to come.The post Why I'd buy the AstraZeneca (AZN) share price for a second income stream appeared first on The Motley Fool UK.

  • Reuters - UK Focus

    GLOBAL MARKETS-European shares hit record even as coronavirus shows no signs of peaking

    Stock markets across the world ticked higher on Friday, even as investors debated whether China's coronavirus outbreak would cause long-lasting damage to the global economy. Europe's broad Euro STOXX 600 hit a record high, gaining 0.2% to mirror gains in Asia after a choppy start to the day. Indexes in London and Frankfurt gained 0.2% and 0.3% respectively, with the former moving higher after AstraZeneca shares turned positive.

  • What to Watch: AstraZeneca warns on coronavirus, RBS rebrand and markets' stimulus hopes
    Yahoo Finance UK

    What to Watch: AstraZeneca warns on coronavirus, RBS rebrand and markets' stimulus hopes

    A daily overview of the top business, market and economic stories you should be watching today in the UK and abroad.

  • AstraZeneca braces for coronavirus hit, but no impact so far
    Reuters

    AstraZeneca braces for coronavirus hit, but no impact so far

    The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019. Analysts are currently forecasting growth of 10%, according to Refinitiv data, although Jefferies analysts said anything below a double-digit estimate could be a disappointment.

  • Reuters - UK Focus

    MORNING BID EUROPE-Virus victim count rises -- and so do global stocks

    China's announcement of more than 5,000 new coronavirus cases and 121 new deaths indicate the epidemic hasn't peaked yet. A pan-European index is in fact opening at record highs, buoyed by … answers on a postcard. The thinking appears to be the virus impact will not last, it’s not spreading outside China as fast as feared and above all, central banks can step in -- slower growth will bring more stimulus, or at least lower interest rates for longer.

  • FTSE 100 ends week lower after week AstraZeneca, RBS results
    Reuters

    FTSE 100 ends week lower after week AstraZeneca, RBS results

    The FTSE 100 index ended the Valentine's Day trading session 0.6% lower, down 0.8% for the week, while the midcap bourse rose 0.5% as it drew strength from the pound. Global markets are expecting stimulus from central banks as new coronavirus showed no signs of peaking. U.S. Federal Reserve Chair Jerome Powell had last week warned that the economic impact from the outbreak could spill over globally.

  • Reuters - UK Focus

    AstraZeneca says 2020 sales growth to take coronavirus hit

    AstraZeneca expects 2020 revenue growth in the high single-digit to low double-digit percentages, including a hit it now expects from the coronavirus outbreak in China, its second biggest market, the British drugmaker said on Friday. The company said the guidance assumed an unfavourable impact from China lasting up to a few months as a result of the outbreak, which has killed over 1,300 people and is still spreading.

  • Reuters - UK Focus

    FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

    The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more